KRAS G12C and G12D Inhibitors: Three Regulatory Milestones in February 2026

Updated on March 20,2026|Written by Patsnap Team

In a single month, February 2026 delivered three KRAS-targeted regulatory events: one full approval (Sosimerasib, China), one Breakthrough Therapy designation for a G12C inhibitor (Calderasib, China), and the first-ever Breakthrough Therapy designation for a KRAS G12D inhibitor (GFH-375, China). The concentration of milestones in one month — and the fact that all three are China-originated — signals how rapidly China’s oncology pipeline has matured in this space.

All pipeline data is sourced from Patsnap Synapse.

Why KRAS Matters

KRAS (Kirsten rat sarcoma viral proto-oncogene) encodes a small GTPase central to cell proliferation signalling via the RAS–RAF–MEK–ERK pathway. Oncogenic mutations lock KRAS in a constitutively active GTP-bound state, driving uncontrolled proliferation. KRAS is the most frequently mutated oncogene in human cancer — mutated in approximately 25% of all cancers, including:

• ~35% of colorectal cancers
• ~32% of pancreatic ductal adenocarcinomas (PDAC)
• ~17% of non-small cell lung cancers (NSCLC)

For decades, KRAS was considered undruggable due to its smooth protein surface and high affinity for GTP. The breakthrough came with the structural identification of a cryptic pocket adjacent to the G12C mutation site that could be covalently targeted. For the foundational science, see this PMC review of the first KRAS G12C inhibitor approvals.

The Three February 2026 Milestones

Patsnap Synapse tracks every approval and ERP designation across FDA, NMPA, EMA, and PMDA in real time — connected to patent, clinical trial, and competitive data. Explore regulatory intelligence →

1. Sosimerasib — China’s first domestic KRAS G12C approval

Developer: Zhejiang Hangyu Pharmaceutical
Target: KRAS G12C
Indication: KRAS G12C-mutant NSCLC
Event: NMPA approval, February 25, 2026 + Conditional Marketing Approval

Sosimerasib is a covalent KRAS G12C inhibitor that targets the GDP-bound (inactive) form of mutant KRAS G12C, forming an irreversible covalent bond with the mutant cysteine residue at position 12. This locks KRAS in the inactive state, preventing downstream RAS pathway activation.

China has now approved three KRAS G12C inhibitors: sotorasib (Lumakras, Amgen — the first in China), adagrasib (Krazati, BMS/Mirati — the second), and now sosimerasib — the first domestically developed agent in this class. The domestic origination is commercially significant: it demonstrates Chinese pharma’s ability to independently discover, develop, and register a KRAS-targeted small molecule, not merely license foreign programs. Simultaneous Conditional Marketing Approval reflects the NMPA’s expedited access strategy for oncology drugs addressing substantial unmet need.

2. Calderasib — Breakthrough Therapy for KRAS G12C in China

Developer: MSD R&D (China) Co., Ltd. (Merck Sharp & Dohme China subsidiary)
Target: KRAS G12C
Indication: KRAS G12C-mutant NSCLC
Event: NMPA Breakthrough Therapy designation, February 13, 2026

Calderasib (also known as MK-1084) is MSD’s KRAS G12C inhibitor in China development. Its Breakthrough Therapy designation from the NMPA — China’s equivalent of the FDA BTD — signals that preliminary clinical data has shown substantial improvement over existing therapies.

The competitive dynamics between calderasib and the already-approved sotorasib, adagrasib, and sosimerasib will hinge on differentiation — whether through improved CNS penetration (brain metastases are common in NSCLC), combination strategies (with PD-1 inhibitors, SHP2 inhibitors, or mTOR inhibitors), or a more favourable adverse event profile.

3. GFH-375 — First-ever Breakthrough Therapy for KRAS G12D

Developer: Genfleet Therapeutics (Shanghai), Inc.
Target: KRAS G12D
Indication: KRAS G12D-mutant NSCLC
Event: NMPA Breakthrough Therapy designation, February 13, 2026

This is the most scientifically significant of the three February milestones. KRAS G12D — where glycine is replaced by aspartate — is the single most common KRAS mutation in human cancer, predominant in PDAC (~40%), CRC (~12%), and lung cancer (~4%). Unlike G12C (cysteine), G12D does not offer a unique reactive group for covalent targeting, making inhibitor design structurally more complex.

GFH-375 receiving a Breakthrough Therapy designation from the NMPA represents the first regulatory acknowledgment globally of a KRAS G12D inhibitor showing sufficient early clinical promise. Multiple programs targeting G12D are in early development worldwide — including MRTX1133 (Mirati/BMS) and RMC-9805 (Revolution Medicines) — but GFH-375’s February 2026 BTD is the first regulatory milestone in this class.

KRAS G12C Inhibitor Competitive Landscape

The G12C space is increasingly crowded at the monotherapy level — differentiation is shifting toward combination strategies, CNS activity (brain metastases are found in ~30% of advanced NSCLC), and activity in non-lung cancers (PDAC, CRC).

KRAS G12D Inhibitor Competitive Landscape

G12D inhibition remains early-stage globally. GFH-375’s Breakthrough Therapy designation is the field’s first regulatory signal — though the therapy is still in Phase 2 and full approval is years away.

Combination Strategies: The Next Frontier

Single-agent KRAS G12C inhibitors produce durable responses in a minority of patients due to adaptive resistance mechanisms — primarily reactivation of RAS signalling through upstream RTK amplification, downstream RAS pathway bypass, and KRAS amplification. The field is now focused on rational combinations:

• KRAS G12C + SHP2 inhibitor (e.g., sotorasib + RMC-4630): blocks upstream RTK-mediated RAS reactivation
• KRAS G12C + MEK inhibitor: directly suppresses MAPK reactivation
• KRAS G12C + PD-1/PD-L1: addresses the immunosuppressive TME in KRAS-mutant NSCLC
• KRAS G12C + EGFR inhibitor: relevant in CRC where EGFR-mediated feedback is a dominant resistance mechanism

Monitor competitor pipeline movements and patent expiry timelines before anyone else with Patsnap Synapse. Get started →

Patsnap Synapse maps the full KRAS inhibitor competitive landscape — all approved agents, Phase 1–3 programs, combination trials, and patent estates — in one connected platform. Explore the KRAS pipeline on Synapse →

Monthly drug approvals, ERP designations, competitor pipeline shifts — Patsnap Synapse helps drug development and BD teams stay ahead of the curve. Request a demo →

Further Reading

• APAC drug approvals — China and South Korea, February 2026
• Global drug approvals roundup — February 2026
• Breakthrough Therapy designations — February 2026

Data sourced from Patsnap Synapse. This post is for informational purposes only.